Observational study to assess the characteristics and outcomes of patients with refractory/relapsed diffuse large B cell lymphoma who received R-GemOx as second line or above treatment (MK-2140-012)

Study summary

No information provided.

Study identification

• EU PAS number:
  EUPAS1000000973
• Study ID:
  1000000973
• Official title and acronym:
  Observational study to assess the characteristics and outcomes of patients with refractory/relapsed diffuse large B cell lymphoma who received R-GemOx as second line or above treatment (MK-2140-012)
• DARWIN EU® study:
  No
• Study countries:
  China
• Study description:
  This epidemiological study aims to provide the real-world data on 2L+ rituximab-gemcitabine-oxaliplatin (R-GemOx) treated patients with refractory/relapsed diffuse large B cell lymphoma (R/R DLBCL) in China. The primary objective of this study is to assess the demographic and clinical characteristics, treatment characteristics, and outcomes among all eligible patients.
• Study status:
  Planned

Research institutions and networks

Institutions

Merck Sharp & Dohme LLC

United States

Study timelines

Date when funding contract was signed

Actual:11/03/2026

Study start date

Planned:30/06/2026

Data analysis start date

Planned:15/12/2026

Date of final study report

Planned:31/03/2027

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Merck Sharp & Dohme LLC

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable